v3.26.1
Equity (Details Narrative) - USD ($)
 6 Months Ended
Jun. 02, 2026
Oct. 03, 2025
Sep. 08, 2025
Feb. 20, 2025
Jun. 30, 2026
Jun. 29, 2026
Dec. 31, 2025
Feb. 25, 2025
Subsidiary or Equity Method Investee [Line Items]                
Aggregate gross proceeds       $ 5,000,000.0        
Common stock, par value         $ 0.01   $ 0.01  
Revenue condition description Company reports quarterly revenue of at least $2.0 million in a fiscal quarter, as evidenced in a Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or certain Current Reports on Form 8-K, the Company may deliver a notice requiring the holder to exercise all or a specified portion of the outstanding Class B Warrants within five business days. Any portion of the called warrants not timely exercised would automatically expire without consideration, subject to the warrant’s beneficial ownership limitations.              
Remaining balance of stock         $ 1,300,000      
Fair value of new warrants issued as part of the inducement     $ 6,700,000          
Common stock shares issued       1,171,189 6,663,489   4,021,293  
Agent Fees [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Number of restricted stock issued         $ 78,213      
Class A Warrants [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Warrants to purchase of common stock 1,882,845              
Exercise price $ 2.14              
Class B Warrants [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Warrants to purchase of common stock 1,882,845              
Exercise price $ 2.14              
2026 Purchase Agreement [Member] | Private Placement [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Number of shares sold 1,882,845              
Purchase price per share $ 2.39              
Aggregate gross proceeds $ 4,500,000              
Common stock, par value $ 0.01              
2025 ATM Agreement [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Common stock, par value   $ 0.01            
Remaining balance of stock   $ 6,413,876     432,843      
ATM Agreement [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Remaining balance of stock         $ 5,100,000      
Inducement Letter [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Exercise price     $ 4.79         $ 3.32
Warrants purchase, shares     1,649,147         1,099,431
Share price     $ 0.125          
Gross proceeds from exercise warrant     $ 3,800,000          
Pre-Funded Warrant [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Exercise price       $ 0.0001        
Warrants purchase, shares       278,098        
Shares Issued, Price Per Share       $ 3.4499        
Warrant [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Exercise price       $ 3.32        
Warrants purchase, shares       1,449,287        
Shares Issued, Price Per Share       $ 3.45        
Warrant exercise description       The Common Warrants were exercisable immediately and expire five and one-half years from issuance        
MedTech [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Number of disposition of common shares or cancel and replacement of existing warrants           507,254    
Number of common shares to be issued           255,267    
Number of shares will be replaced by pre-funded common stock purchase warrants           251,987    
MedTech [Member] | September 2025 Warrant [Member]                
Subsidiary or Equity Method Investee [Line Items]                
Class of warrant to purchase shares will be cancelled and replaced           760,881    
Warrants to purchase of common stock           1,268,135    
Exercise price           $ 2.14